Introduction:

Hepatitis Test Solution Market was valued at US$ 3.1 Billion in 2024 and is projected to grow at a CAGR of 4.50 % to reach US$ 4.8 Billion by 2034.

[PDF] The term "hepatitis" refers to the various types of liver inflammation. It is also distinguished into different types, Hepatitis A, B, and C. Blood tests for each virus and an approach to detecting viral-related antibodies are used to diagnose hepatitis. In addition, genetic material or proteins in the body that are components of the virus, can be tested in order to determine the type of hepatitis.

Rising awareness about the benefits of testing of hepatitis virus helping to plot the correct course of treatment and prevention have become the key factors in the growth of the Hepatitis Test Solution Market. The changing lifestyle and food consumption habit, increasing medication side effects, excessive consumption of alcohol, growing rates of autoimmune disorders and viral hepatitis, increasing disposable income of consumers, growing numbers of undiagnosed people in the population and increased medical tourism has also become the major contribution in Hepatitis Test Solution Market growth.

 

Increasing launches of new drugs and regulatory approvals for hepatitis drugs to drive the growth of hepatitis test solution market 

Increasing regulatory authority approvals for hepatitis medications is anticipated to fuel the growth of Hepatitis Test Solution Market expansion over the course of the estimate period.

For instance, in January 2016, U.S Food and Drug Administration (FDA) approved Zepatier (elbasvir and grazoprevir) treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections, with or without ribavirin. In clinical trials, Zepatier's effectiveness and safety were assessed in 1,373 patients with chronic HCV genotype 1 or 4 infections, both with and without cirrhosis. For 12 or 16 weeks, the participants took Zepatier once daily with or without ribavirin.

Launch of new drugs for hepatitis treatment is expected to drive the growth of Hepatitis Test Solution Market during the course of time.

Furthermore, in 2018, Natco Pharma, a pharmaceutical company committed in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”) fixed dose combination of “Sofosbuvir-Daclatasvir tablets” for the treatment of Hepatitis C under the brand name Hepcinat Plus. Sofosbuvir-Daclatasvir tablets is a generic fixed dose combination comprised of Sofosbuvir 400 mg and Daclatasvir 60mg tablets. Its maximum retail price is 17,500 for a bottle of 28 tablets.

High burden of hepatitis disease

Despite of the substantial advancements in treatment options, immunization coverage, and public awareness, hepatitis remains a serious public health concern with a high prevalence rate worldwide. Hepatitis types B and C are the most common and are associated with increased fatality rates. The rise in prevalence of hepatitis over the forecast period has driven the Hepatitis Test Solution Market growth.

For instance, in 2022, according to the World Health Organization (WHO), in World Hepatitis Summit, it is estimated that 354 million people worldwide are still living with this life-threatening infection and at least one person dies from viral hepatitis every 30 seconds, that is equals to over 1 million deaths per year suffering from Hepatitis B virus (HBV) and hepatitis C virus (HCV). Over 700 cases of sudden and unexplained hepatitis in young children have come into lime light.

Restrains:

Hepatitis drugs are expensive to produce because they need labor-intensive production processes, high-priced pharmacological intermediates, and expensive active pharmaceutical ingredients (APIs). Consequently, a large amount of money is needed for the development and marketing of medications for the treatment of hepatitis, thus it restrains the target market growth and impedes the growth of the Hepatitis Test Solution Market.  Furthermore, factors such as pro-longed development process and approval time of pharmaceutical drugs further limits the growth of Hepatitis Test Solution Market.

 

Hepatitis Test Solution market is segmented based on Type, Application and Region.

Type Insight

On the basis of Type, Hepatitis Test Solution Market is segmented into Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), and Isothermal Nucleic Acid Amplification Technology (INAAT).  Enzyme-Linked Immunosorbent Assay (ELISA) segment is expected to dominate the target market growth due to its simpler procedure, high specificity and sensitivity, because of an antigen–antibody reaction, High efficiency, as simultaneous analyses can be performed without complicated sample pre-treatment.

Application Insights

On the basis of Application, Hepatitis Test Solution Market is segmented into Hospitals, Diagnostic Laboratories, Nursing Homes, and Blood Banks. Hospitals segment, are expected to dominate the target market growth due to the availability of cutting-edge facilities and advancements in healthcare infrastructure in emerging countries. In addition, the rise of facilities in hospitals that specialize in hepatitis testing and diagnosis is another factor driving the growth of this segment.

Regional Insights:

On the basis of region, the Hepatitis Test Solution Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as advanced diagnostic tools, high awareness regarding the disease and diagnostic devices, the strong presence of key industries in the region. Better healthcare infrastructure, and higher awareness among healthcare industry stakeholders about available technologies in the region are anticipated to increase demand for hepatitis test solution in the region.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), and Isothermal Nucleic Acid Amplification Technology (INAAT) By Application - Hospitals, Diagnostic Laboratories, Nursing Homes, and Blood Banks
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Hepatitis Test Solution market report based on Type, Application and Region:

Hepatitis Test Solution Market, By Type:

• Polymerase Chain Reaction (PCR)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Rapid Diagnostic Tests (RDT)
• Isothermal Nucleic Acid Amplification Technology (INAAT)  

Hepatitis Test Solution Market, By Application:

• Hospitals
• Diagnostic Laboratories
• Nursing Homes
• Blood Banks

Hepatitis Test Solution Market, By Region:

 

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Hepatitis Test Solution Market includes, Hoffmann-La Roche AG Abbott Laboratories, DiaSorin S.p.A, Bio-Rad Laboratories, Inc., Siemens AG, QIAGEN, bioMérieux SA, Grifols, S.A., and Danaher Corporation.

Recent Development:

• In July 2022 New Hepatitis C virus diagnostic test is released by Roche. Elecsys HCV Duo immunoassay is a new dual antigen and antibody diagnostic test that has been developed for the in vitro qualitative assessment of antibodies to the hepatitis C virus (HCV) and core antigen (HCV Ag) from human serum and plasma samples. It provides early detection of HCV infection and aids in preventing the virus' spread to the patient's tissue, blood components, blood, cells, or organs.
• In 29 June 2022, Liver care Canada, a subsidiary of Mednow Inc. partnered with HepCURE, a non-profit company and one of Canada’s leading hepatitis C screening and treatment providers for the eradication of hepatitis C in Canada by 2030. The partnership signifies an evolution in the industry by dismantling and getting rid of rivalry that will only serve to help individuals that requires care and treatment. Liver care Canada offers the patients access to HepCURE’s programming and services that will further improves the medication adherence and optimize the treatment outcomes.

• Hoffmann-La Roche AG Abbott Laboratories *

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies

• DiaSorin S.p.A
• Bio-Rad Laboratories. Inc.
• Siemens AG
• QIAGEN
• bioMérieux SA
• Grifols, S.A.
• Danaher Corporation

“*” marked represents similar segmentation in other categories in the respective section